Abstract: There are disclosed herein antigenic structures useful in producing vaccines against and compounds helpful in combating diseases caused by the bacterium Moraxella catarrhalis. Disclosed are specific structures of the carbohydrate molecules derived from genetically engineered strains of Moraxella catarrhalis, which when presented appropriately to the immune system will facilitate a functional immune response to the target core oligosaccharide region.

Abstract: An increasing amount of the world's content resides on the web in a form targeted to web browser rendering. It may be advantageous to utilize this web content within non-web-based rich client applications because such rich client applications may provide robust features and/or interactions that web-based platforms lack. Unfortunately, integrating web content into non-web user interfaces may be a difficult task. Accordingly, one or more systems and/or techniques for rendering web content within a user interface are disclosed herein. In particular, a composition component may be configured to invoke one or more rendering components to generate rendered web content in a common format within a surface. The rendered web content may be provided to a user interface for display. An input component may be configured to invoke a rendering component to update rendered web content based upon interaction with rendered web content within the user interface.

Abstract: The removal of the glycosidic phosphate from the reducing end of the derived LPS molecule creates an aldehydo functionality which causes the formation of an immunologically dominant neo-epitope. Conjugation to the reducing end of a carbohydrate molecule following removal of the glycosidic phosphate traps the reducing glucosamine residue in an open-chain form which surprisingly was found to dominate the immune response. We therefore modified our conjugation strategy to avoid this open-chain form, by utilising the amino functionality created by the isolated amidase activity from Dictyostelium discoideum, concomitant with a unique blocking and un-blocking strategy to protect the immunologically important phosphoethanolamine inner core residue. These antigenic structures are useful in producing vaccines and compounds helpful in combating Gram-negative bacteria.

Abstract: The viewing functionality of an application may be extended by use of an adapter. An application is instantiated, and the application may provide a view box that contains a scrolling feature as part of its interface. The adapter uses the application “behind the scenes” to collect information in a way that is not visible to the user. Mouse gestures may be defined to perform various viewing functions such as zooming. The adapter intercepts these gestures in the window that the user uses to interact with the application, and interprets the gestures as specific view commands (such as zoom). Based on the commands (or, possibly, in anticipation of commands that have not yet been issued), the adapter uses the application to collect content. The application then scales the content appropriately, puts the scaled content in a document, and overlays the document on top of the view box.

Abstract: There are disclosed herein antigenic structures useful in producing vaccines against and compounds helpful in combating diseases caused by the bacterium Moraxella catarrhalis. Disclosed are specific structures of the carbohydrate molecules derived from genetically engineered strains of Moraxella catarrhalis, which when presented appropriately to the immune system will facilitate a functional immune response to the target core oligosaccharide region.

Abstract: A conserved inner-core oligosaccharide epitope expressed on the lipopolysaccharide (LPS) of a range of disease causing pathogenic bacterial isolates, including Actinobacillus pleuropneumoniae (Ap), Mannheimia haemolytica (Mh) and Pasteurella multocida (Pm), is disclosed. Construction of a mutant bacterial strain exclusively expressing the conserved inner core OS epitope as a terminally exposed structure has allowed the identification, production and isolation of an inner core LPS which is common to all three organisms. Further provided are associated vaccines, antibodies raised against the conserved LPS inner core and glycoconjugates comprising the LPS inner core linked to an immunogenic carrier.

Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.

Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.

Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.